The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Top highlights from ASH 2024 in the MPN field
John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, NY, highlights some of the top updates and abstracts presented in the myeloproliferative neoplasms (MPNs) field at the ASH 2024 meeting.
Dr Mascarenhas outlines some advancements and the emerging therapeutic approaches being investigated, such as novel JAK inhibitors, MDM2 inhibitors, and selinexor combination therapy. He also highlights encouraging updates from the follow-up of the MANIFEST-2 trial, which demonstrated durability of spleen response and symptom response. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
Well, I think there’s a lot going on in MPNs in general. There’s a lot of data looking at the influence of mutations both for risk stratification and prognostication, including TP53 on which there are two abstracts highlighting the adverse prognostic impact of TP53 mutations both from a survival standpoint but also a leukemic transformation standpoint.
And then there’s a ton of data emerging on new JAK2 inhibitors, some agents coming from China, as well as non-JAK inhibitor therapies with MDM2 inhibitors, imetelstat (the telomerase inhibitor), and then we’re waiting for data to read out, for example, from the INDEPENDENCE study with luspatercept, the Selinexor-Karyopharm Phase III study of combination selinexor plus ruxolitinib...
Well, I think there’s a lot going on in MPNs in general. There’s a lot of data looking at the influence of mutations both for risk stratification and prognostication, including TP53 on which there are two abstracts highlighting the adverse prognostic impact of TP53 mutations both from a survival standpoint but also a leukemic transformation standpoint.
And then there’s a ton of data emerging on new JAK2 inhibitors, some agents coming from China, as well as non-JAK inhibitor therapies with MDM2 inhibitors, imetelstat (the telomerase inhibitor), and then we’re waiting for data to read out, for example, from the INDEPENDENCE study with luspatercept, the Selinexor-Karyopharm Phase III study of combination selinexor plus ruxolitinib. And there’s a lot going on.
Still haven’t seen data yet on the mutant CALR antibody approach or bispecific antibody approach. And it’s still early to look at type 2 JAK2 inhibitor or JAK2V617F selective inhibitor data. So I think a lot is being presented today, these days, but more to come in future meetings.
The other trial I think that is worthy of highlighting is MANIFEST2, which continues to be followed up. At this ASH, we’re presenting week 48 data, demonstrating durability of spleen response and symptom response, but also these biomarkers of disease modification, whether it’s bone marrow fibrosis reduction or driver mutation, and we continue to follow patients both for their overall outcomes and also any imbalances in blast transformation.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
CTI BioPharma/SOBI: Consultancy, Research Funding; Celgene: Consultancy, Other: Travel Support, Speakers Bureau; MorphoSys: Consultancy; Merck: Consultancy; PharmaEssentia: Consultancy, Research Funding; Disc: Consultancy; GSK: Consultancy; Blueprint Medicines: Consultancy; Ariad: Speakers Bureau; Novartis: Consultancy, Other: Travel Support , Research Funding, Speakers Bureau; Sumitomo: Consultancy; Karyopharm: Consultancy; Pfizer: Research Funding; Keros: Consultancy; Bristol Myers Squibb: Research Funding; Icahn School of Medicine at Mount Sinai: Current Employment; Ajax: Research Funding; Roche: Consultancy; Geron: Consultancy, Research Funding; Kartos: Consultancy, Research Funding; AbbVie: Consultancy, Research Funding; NS Pharma: Research Funding; Incyte Corporation: Consultancy, Speakers Bureau; Astellas: Research Funding.
